RxDoctor Payments Data

Candace Marr, DO

Internal Medicine · Buffalo, NYNPI 1922341775

Payments from drug & device makers

$1,149in general payments, 2019–2025

Across 50 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$242
  • Insmed, Inc.$215
  • Merck$143
  • Shionogi Inc$92
  • Solventum Corporation$71
  • Johnson & Johnson$66
  • plus $321 from 9 others

What the payments were for

  • Food & beverage$87376%
  • Education$27624%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,149 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$53,210
Medicare patients
180
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate23$276,040
BiktarvyBictegrav/Emtricit/Tenofov Ala42$179,565
Methenamine Hippurate111$6,769
Cefpodoxime Proxetil44$4,681
Cefepime Hcl14$3,423
Doxycycline Hyclate131$2,372
Vancomycin Hcl25$2,337
Clobetasol EmollientClobetasol Propionate/Emoll18$2,205
Cefdinir52$1,989
Cephalexin93$1,761
Linezolid20$1,726
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim118$1,542
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav61$1,445
Doxycycline Monohydrate44$1,440
Fluconazole61$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$66$276,04023 claims
GileadBiktarvy$26$179,56542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →